SGLT-2 inhibitors as second-line therapy in type 2 diabetes

Research output: Contribution to journalComment/debate

Authors

Colleges, School and Institutes

External organisations

  • Centre for Endocrinology, Diabetes, and Metabolism (CEDAM); School of Clinical and Experimental Medicine; University of Birmingham; Institute of Biomedical Research; UK
  • Department of Diabetes and Endocrinology
  • Birmingham Heartlands Hospital, Birmingham, UK.

Details

Original languageEnglish
Pages (from-to)678-679
Number of pages2
JournalThe Lancet Diabetes and Endocrinology
Volume2
Issue number9
Publication statusPublished - 1 Sep 2014